Doc is right this stock is going to explode. With this kind of results, it will rise sharply when it gains enough attention.
press release
June 22, 2011, 9:17 a.m. EDT
Global Health Ventures Completes European Clinical Trials Phase I for X-Excite vs. Viagra(R)
VANCOUVER, British Columbia, Jun 22, 2011 (GlobeNewswire via COMTEX) -- Global Health Ventures Inc. /quotes/zigman/529382 GHLV +2.86% , a specialty pharmaceutical company with focus on sublingual drug delivery is pleased to announce that it has completed the clinical trials, a pharmacokinetics (PK) study in Europe under EMEA guideline and the final report has been obtained.
In the study, 12 subjects were given 25 mg sildenafil base from Pfizer, oral formulation known as Viagra(R) and another 12 subjects were given 25 mg sildenafil citrate (20.6 mg X-Excite). Blood was taken from each tested subject at 1, 15, 20, 30 and 45 minutes and then 1, 2, 3, 5, 8, and 12 hours. The plasma samples were analyzed for sildenafil concentration with a method that has a lower limit of quantification (LLOQ) of 2 ng/ml. The primary objective was the blood pharmacokinetic analysis, maximal drug concentration and time from administration to maximal concentration in plasma (Cmax and Tmax), as well as area under plasma time/concentration curve from 0 to 8 hours of sildenafil (AUC).
The results in summary, showed, X-Excite to appear in the blood significantly faster than Viagra(R), stay in the blood longer, and based on actual sildenafil drug used, have a greater AUC. Furthermore, none of the subjects which received X-Excite, dropped out of trials nor any complications were observed. The trials provided the expected and successful end point.
"We are very pleased with the completion of our European trials and now we are proceeding with the clinical trials in the United States under the FDA guideline. First step in the U.S. trial, is to produce the drug in an FDA approved GMP facility. We have already started the process of manufacturing of our drug for U.S. clinical trials," said Dr. Hassan Salari, Chairman and CEO of Global Health Ventures Inc.
